[4,5,6] In August 2022, based on data from DESTINY-Lung02, the FDA granted accelerated approval of the antibody–drug conjugate trastuzumab–deruxtecan, making it the first targeted agent approved for HER2-mutant NSCLC [6,7]. Here, ERBB2 is linked to non-small cell lung carcinoma.